Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast

Local recurrence is used as a marker of treatment failure for patients with ductal carcinoma in situ (DCIS). As follow-up lengthens, distant recurrence, breast cancer–specific survival (BCSS), and overall survival must be monitored. A prospective database was used to analyze 1031 patients with DCIS....

Full description

Saved in:
Bibliographic Details
Published in:The American journal of surgery 2004-10, Vol.188 (4), p.371-376
Main Authors: Romero, Lina, Klein, Laura, Ye, Wei, Holmes, Dennis, Soni, Rashida, Silberman, Howard, Lagios, Michael D., Silverstein, Melvin J.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Breast cancer
Breast cancer–specific survival
Breast Neoplasms - mortality
Cancer therapies
Carcinoma in Situ - mortality
Carcinoma, Ductal, Breast - mortality
Ductal carcinoma in situ
Fatalities
Female
Follow-Up Studies
General aspects
Gynecology. Andrology. Obstetrics
Humans
Invasive recurrence
Local recurrence
Mammary gland diseases
Mammography
Medical research
Medical sciences
Mortality
Neoplasm Invasiveness
Neoplasm Recurrence, Local - mortality
Probability
Prospective Studies
Radiation therapy
Survival Rate
Therapy
Time Factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Local recurrence is used as a marker of treatment failure for patients with ductal carcinoma in situ (DCIS). As follow-up lengthens, distant recurrence, breast cancer–specific survival (BCSS), and overall survival must be monitored. A prospective database was used to analyze 1031 patients with DCIS. Patients having invasive recurrence after DCIS treatment were compared with patients having infiltrating ductal carcinoma (IDC). End points included distant recurrence, BCSS, and overall survival. Overall, patients with DCIS had a BCSS of 99%. BCSS was 85% for patients with invasive recurrences. DDFS in this group was 80%. Stage I IDC patients had a BCSS of 91%, whereas it was 38% in those with stage I IDC and invasive recurrences. Most patients with DCIS that recur can be salvaged. For the small subgroup of patients who recur with invasive breast cancer, survival is similar to that of patients with stage IIA IDC.
ISSN:0002-9610
1879-1883
DOI:10.1016/j.amjsurg.2004.06.034